CD326 (EpCAM) MicroBeads can be used for the:
- positive selection or depletion of epithelial cells or epithelial tumor cells from single-cell preparations of tissues and organs,
- enrichment of circulating or disseminated epithelial tumor cells expressing CD326 from peripheral blood, bone marrow, or even lymph nodes, serous effusions, or stool samples1 of patients with carcinomas,
- positive selection of functional pluripotent hepatic progenitor cells (hepatic stem cells and hepatoblasts) from fetal, neonatal, pediatric, and adult liver tissue2,3
Related products for CD326 (EpCAM) MicroBeads, human
CD326 (EpCAM) MicroBeads can be used for the:
- positive selection or depletion of epithelial cells or epithelial tumor cells from single-cell preparations of tissues and organs,
- enrichment of circulating or disseminated epithelial tumor cells expressing CD326 from peripheral blood, bone marrow, or even lymph nodes, serous effusions, or stool samples1 of patients with carcinomas,
- positive selection of functional pluripotent hepatic progenitor cells (hepatic stem cells and hepatoblasts) from fetal, neonatal, pediatric, and adult liver tissue2,3,
- positive selection of tumor exosomes from peripheral blood4,
- enrichment of exfoliated epithelial cells from gastric aspirates and stool samples of preterm infants5,
- purification of primary tumor cell cultures6.
CD326, also known as human epithelial antigen (HEA), epithelial cell adhesion molecule (EpCAM), or epithelial-specific antigen (ESA) expression is seen in the majority of carcinomas. It is expressed on cells of epithelial origin, epithelium-derived tumor cells7, circulating tumor cells, and cancer stem cells.
Tumor cells enriched by CD326 (EpCAM) MicroBeads can be cultured8 and analyzed by immunocytochemistry9, flow cytometry, or molecular biology techniques, for example, RT-PCR10.
MS, LS, XS, or autoMACS® Columns.
Enrichment of tumor cells from PBMCs spiked with cells of the breast cancer cell line BT474. Separation was performed using an MS Column and CD326 (EpCAM) MicroBeads.
CD326 (EpCAM)+ tumor cells isolated from pleural effusion of a patient with adeno-carcinoma using CD326 (EpCAM) MicroBeads, an MS Column, and a MiniMACS™ Separator. Cells were stained with CD326 (EpCAM)-FITC and Anti-FITC Alkaline Phosphatase plus substrate.(Courtesy of Dr. Motherby and Prof. Böcking, Inst. of Cytopathol., Univ. Düsseldorf, Germany.)
CD326 (EpCAM)+ tumor cells isolated from pleural effusion of a patient with adeno-carcinoma using CD326 (EpCAM) MicroBeads, an MS Column, and a MiniMACS™ Separator. Cells were stained with CD326 (EpCAM)-FITC and Anti-FITC Alkaline Phosphatase plus substrate.(Courtesy of Dr. Motherby and Prof. Böcking, Inst. of Cytopathol., Univ. Düsseldorf, Germany.)
- Schmelzer, E. et al. (2006) The phenotypes of pluripotent human hepatic progenitors. Stem Cells 24: 1852-1858
- Schmelzer, E. et al. (2007) Human hepatic stem cells from fetal and postnatal donors. J. Exp. Med. 204: 1973-1987
- Lewin, M. H. et al. (2006) Red meat enhances the colonic formation of the DNA adduct O6-carboxymethyl guanine: implications for colorectal cancer risk. Cancer Res. 66: 1859-1865
- Moldenhauer, G. et al. (1987) Epithelium specific surface glycoprotein of Mr 34,000 is a widely distributed human carcinoma marker. Br. J. Cancer 56: 714-721
- Taylor, D. D. and Gercel-Taylor, C. (2008) MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 110: 13-21
- Molloy, T. J. et al. (2008) Towards an optimized platform for the detection, enrichment, and semi-quantitation circulating tumor cells. Breast Cancer Res Treat 112: 297-307
- Krüger, W. et al. (2000) Immunomagnetic tumor cell selection--implications for the detection of disseminated cancer cells. Transfusion 40: 1489-1493
- Kaeffer, B. et al. (2007) Recovery of exfoliated cells from the gastrointestinal tract of premature infants: a new tool to perform "noninvasive biopsies?". Pediatr. Res. 62: 564-569
- Leinung, S. et al. (2000) Cytokeratin‑positive cells in bone marrow in comparison with other prognostic factors in colon carcinoma. Langenbecks Arch. Surg. 385: 337-343
You have previously chosen International as your location.
What do you want to do?